| VIKING THERAPEUTICS |
| USA |
| Gesundheit |
| US92686J1060 / A12GD6 |
| 1VT (Frankfurt) / VKTX (NASDAQ) |
| FRA:1VT, ETR:1VT, 1VT:GR, NASDAQ:VKTX |
| - |
| https://www.vikingtherape.. |
|
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for metabolic and endocrine disorders. Viking Therapeutics is advancing a pipeline that includes VK2735, a dual GLP-1/GIP receptor agonist being s..
>Volltext.. |
| 3294.74 Mio. EUR |
| 2668.48 Mio. EUR |
| - |
| -584.23 Mio. EUR |
| -565.41 Mio. EUR |
| -4.87 EUR |
| 229.6 Mio. EUR |
| 610.85 Mio. EUR |
| -417.06 Mio. EUR |
| 7.17 |
| - |
| -173.67% |
| - |
| - |
| - |
| - |
| VIKING THERAPEUTICS, VIKING THERAPEUTIC |
| 13.11.26 |
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|
||||
|